Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.49 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5591234 | 1.00 | MAPT (0.58) | MAPTSIGMAR1FUCA1GBA1CYP3A4 | |
| SCHEMBL16043911 | 1.00 | MAPT (0.58) | MAPTSIGMAR1FUCA1GBA1CYP3A4 | |
| SCHEMBL16044726 | 1.00 | MAPT (0.58) | MAPTSIGMAR1FUCA1GBA1CYP3A4 | |
| SCHEMBL566922 | 1.00 | MAPT (0.58) | MAPTSIGMAR1FUCA1GBA1CYP3A4 | |
| SCHEMBL2079349 | 0.87 | MAPT (0.55) | MAPTSIGMAR1FUCA1 | |
| SCHEMBL3898603 | 0.87 | MAPT (0.55) | MAPTSIGMAR1FUCA1GBA1CYP3A4 | |
| SCHEMBL1974795 | 0.87 | MAPT (0.55) | MAPTSIGMAR1FUCA1GBA1CYP3A4 | |
| SCHEMBL30420145 | 0.87 | MAPT (0.55) | MAPTSIGMAR1FUCA1GBA1CYP3A4 | |
| SCHEMBL7941754 | 0.87 | MAPT (0.55) | MAPTSIGMAR1FUCA1GBA1CYP3A4 | |
| Hydrochloric Acid SCHEMBL11674164 | 0.86 | MAPT (0.54) | MAPTSIGMAR1FUCA1GBA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272824-A2 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3622956-B9 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3622956-B1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3622956-A1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2020-03-18 | — | — | EP | disclosed |
| EP-3363438-B1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-18 | — | — | EP | disclosed |
| US-9845333-B2 | Substituted 2-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-19 | — | — | US | disclosed |
| US-9845333-B2 | Substituted 2-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-19 | — | — | US | disclosed |
| US-20170204096-A1 | Substituted 2-Azabicycles And Their Use As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | US | disclosed |
| US-20170204096-A1 | Substituted 2-Azabicycles And Their Use As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | US | disclosed |
| US-9611277-B2 | Substituted 2-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2007023382-A2 | PYRIMIDINE AMINO PYRAZOLE COMPOUNDS, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023382-A2 | PYRIMIDINE AMINO PYRAZOLE COMPOUNDS, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-0900204-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6124312-A | ACTIVE DRUG FOR TREATING ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0900204-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040016-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| US-5397800-A | Gastrointestinal disorders | PFIZER INC. (US) | 1995-03-14 | — | — | US | disclosed |
| EP-0510129-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 1992-10-28 | — | — | EP | disclosed |
| WO-1992005172-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | MAPT 3074/4885SIGMAR1 3810/4885FUCA1 4653/4885 |
| US-20170204096-A1 | Substituted 2-Azabicycles And Their Use As Orexin Receptor Modulators | HCRTR2, HCRTR1, NPY2R | MAPT 4270/4885SIGMAR1 91/4885FUCA1 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.